CEL-SCI bereits +300% in 4 Wochen - 500 Beiträge pro Seite

[Turbocash]

Hallo zusammen!

Diese Aktie scheint hier im Board noch nicht viel
Aufmerksamkeit zu haben.Schaut euch mal den Chart an.

Bitte um Eure Meinung.

[Turbocash]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[elmood]

bloss nicht in Berlin kaufen (siehe auch Celeris), weil zu markteng. Nasdaq zahlt sich trotz der hohen Spesen aus, sollte der Wert auch nur ein wenig unter Druck geraten (und sei´s wegen Gewinnmitnahmen).

Mir gefällt der Wert, ich werde auch am Di. oder Mi. einsteigen (mal sehen, wie sich der NASDAQ erholt).

elmood

[elmood]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Turbocash]

Das neue Amex Kurzzeichen ist: CVM

Vielleicht war dieser Artikel der Grund fuer den Kursanstieg:

CEL-SCI Corporation Reports Promising Results of Phase II Cancer Study; Multikine(TM) Immunotherapy Study Presented at BIO CEO & Investor Conference


February 15, 2000 10:30 AM
VIENNA, Va., Feb. 15 /PRNewswire/ -- Patients with advanced head and neck cancer receiving CEL-SCI`s immunotherapeutic product, Multikine, prior to surgery or radiation showed promising tumor reductions, according to the results from a clinical trial presented today by Geert Kersten, CEO of CEL-SCI Corporation (Amex: CVM) (Berlin Stock Exchange: LSR), at the BIO CEO & Investor Conference in New York City. The 30-patient Phase II dose escalating trial revealed that 65% (13 of 20) of the patients treated with the lower two doses of Multikine over 18 days showed tumor reductions. Of those, 39% (5 of 13) showed a greater than 50% tumor mass reduction. Multikine was well-tolerated and the treatment showed minimal toxicity.
Multikine is a mixture of immune system regulators known as cytokines. One of those is Interleukin-2, which is presently being used to treat cancer. The goal of this trial was to induce and expand targeted anti-tumor immunity at the tumor site to reduce tumor mass prior to surgery or radiation. Tumor mass reduction, which can be viewed as entially improving patient outcome, is thought to be an indicator that local anti-tumor immunity may have been achieved.

More specifically: -- At the middle dose level, 70% (7 of 10) of the patients had tumor reductions after the 18-day treatment with Multikine prior to surgery or radiation. Three of those seven patients had tumor reductions in excess of 50% in this short period of treatment. The three patients who did not show tumor reductions remained stable.

-- At the lowest dose level, 60% (6 of 10) of the patients had tumor reductions after the 18-day treatment with Multikine prior to surgery or radiation. Two of those six had over 50% tumor reduction during treatment. Three patients remained stable and one showed disease progression.

-- At the highest dose level, 30% (3 of 10) of the patients had tumor reductions while the rest remained stable.


In this study, which was conducted at medical centers in Poland and the Czech Republic, Multikine was given to recently diagnosed head and neck cancer patients with advanced disease. Each patient volunteer was given 6 injections of Multikine over 18 days.

The success of this regimen will ultimately be measured by its effects on the overall recurrence rate in these patients and on quality of life. Currently, about half of advanced head and neck cancer patients have a recurrence of the cancer and the prognosis for these patients is very poor. Many scientists believe that inducing an immune response directed against tumor cells prior to surgical treatment of the tumor will increase the chance of the surgeon achieving higher cure rates or increasing disease-free time. Thus, even a small tumor response to Multikine treatment achieved during this brief treatment before surgery may be sufficient to achieve this goal. A pivotal trial will need to be conducted to strate higher cure rates or increased disease-free time in a larger number of patients.

Head and neck cancer is the sixth most frequent cancer worldwide, with an incidence of 500,000 cases annually. Recent statistics show no reduction in head and neck cancer mortality, but rather a dramatic increase of the disease in certain segments of the population. It occurs mostly in men in their 50s or early 60s. Conventional treatments consist of either surgery, which can be extremely disfiguring, or radiation therapy and chemotherapy, both of which have severe side effects.

The ential market for a more effective first-line or adjunctive treatment for head and neck cancer is about $1 billion.

In keeping with the appropriate scientific rigor, the Company plans to present more detailed results at an appropriate scientific meeting and to publish them in an appropriate scientific journal.

CEL-SCI Corporation is a biopharmaceutical company whose mission is to harness the immune system to combat disease.

CEL-SCI press releases are available through Company News On-Call by fax, [phone], Ext. 445563, or at http://www.cel-sci.com on the Internet.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results, timely development of any ential products that can be shown to be safe and effective, delays in receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s ential products and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1999. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation